CVS Health (CVS) Stock Looks Reasonable On Fresh Vaccine Access News

CVS Health, the integrated pharmacy and health services group, has delivered a 35.0% share price gain over the past three years, which puts fresh attention on whether its current US$86.16 price fairly reflects what the business earns today. With the stock giving back some ground in recent weeks, investors are again asking how much of CVS Health's earnings story is already in the quote.

• The 35.0% return over three years has rewarded patient holders, which raises the question of how much of that journey has simply pulled future earnings expectations forward.
• Fresh headlines around expanded MMR vaccinations, extended drug distribution agreements and Medicare Advantage offerings can shape how durable CVS Health's earnings base looks and how predictable future cash generation may be.
• There is a second opinion on CVS Health worth weighing. See what analysts think CVS Health's shares could be worth.

The issue now is whether CVS Health's current share price is adequately supported by the earnings power that investors can see in the business today.

For context on whether CVS Health's recent 35.0% three year return aligns with what you look for in earnings backed stories, it can help to compare this performance against solid balance sheet and fundamentals stocks screener (25 results).

Is CVS Health a Bargain on Earnings?

The P/E ratio fits CVS Health because earnings are still the main yardstick most investors use to weigh large healthcare groups that mix insurance, retail and pharmacy benefits.

At roughly 22.5x earnings, CVS Health trades on a higher multiple than its peer group near 18.7x, yet slightly below the broader Healthcare sector around 24.3x. The fair multiple implied by a model that factors in the group’s margins, growth profile, industry and risk sits above the current P/E, which points to the stock screening as undervalued on this framework. Because the recent MMR vaccination push, extended drug distribution contracts and Aetna Medicare Advantage positioning all feed into how reliable future profits might look, the current P/E level invites investors to weigh how durable that earnings stream feels against the discount the model flags. Explore the numbers behind CVS Health's P/E valuation.

The CVS Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for CVS Health pick up where the P/E puzzle leaves off and set out which paths for revenue growth, margins and earnings would need to occur for the stock to appear meaningfully stronger or weaker than today’s price. Each scenario explains the key building blocks behind its view of fair value in plain terms so you can track those assumptions against CVS Health's reported results over time and decide which narrative aligns most closely with your own view.

One of the top community narratives on CVS Health: 17% undervalued

"CVS is no longer trying to be a faster pharmacy. It’s trying to be a more complete healthcare system…"

Discover why this Narrative puts CVS Health at 17% undervalued.

One more factor to weigh before making a call on CVS Health

Everything so far has focused on what CVS Health looks like today, yet professional analysts also map out where they expect this business to be several years from now, and that reference point can change how you read the current price. Explore where analysts expect CVS Health to be in a few years.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com